CYP1A2 Gene Polymorphism and Theophylline Level in Asthma

Lorensia, Amelia and Ikawati, Zullies and Andayani, Tri Murti and Maranatha, Daniel and Wahjudi, Mariana (2019) CYP1A2 Gene Polymorphism and Theophylline Level in Asthma. The Indonesian Biomedical Journal, 11 (1). pp. 63-69. ISSN 2085-3297, Online ISSN: 2355-9179

[thumbnail of CYP1A2 Gene Polymorphism_2019.pdf]
CYP1A2 Gene Polymorphism_2019.pdf

Download (11MB) | Preview
Official URL / DOI:


BACKGROUND: Aminophylline (theophylline) is one of the most frequent asthma therapies in Indonesia, although it remains as a narrow therapy. The effects of drugs are individualized and strongly influenced by genetic, one of which is CYP1A2 gene polymorphisms. This study aimed to determine the profile of CYP1A2 polymorphism and theophylline level in asthma exacerbation patients receiving intravenous aminophylline therapy. METHODS: This cross sectional study was conducted in the emergency room (ER), to adults asthma exacerbation patients without complication (n=27), visiting the ER. The gene polymorphism data were compared with theophylline levels in the blood using chi-square test. RESULTS: In the CYP1A2 gene polymorphism profile, the most common heterozygous alleles are T/G genotype of CYP1A2*1E and C/A genotype of CYP1A2*1F. Most homozygote alleles exist in CYP1A2*1D and CYP1A2*1F. There was significant difference between CYP1A2*1D (p<0.005), CYP1A2*1E (p<0.023) and CYP1A2*1F (p<0.000) polymorphisms and theophylline level. CONCLUSION: CYP1A2*1D, CYP1A2*1E and CYP1A2*1F gene polymorphisms had an effect on theophylline levels. However, no one experienced an overdose theophylline, and no correlation between theophylline levels with CYP1A2 gene polymorphism.

Item Type: Article
Uncontrolled Keywords: exacerbation asthma, intravenous aminophylline, CYP1A2 polymorphism gene, theophylline
Subjects: R Medicine > RS Pharmacy and materia medica
Divisions: Faculty of Pharmacy > Department of Pharmacy
Depositing User: Ester Sri W. 196039
Date Deposited: 17 Jun 2019 02:13
Last Modified: 05 Nov 2020 06:31

Actions (login required)

View Item View Item